RecruitingPhase 3NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ArriVent BioPharma, Inc.
- Principal Investigator
- Morgan LamArriVent BioPharm
- Intervention
- Firmonertinib(drug)
- Enrollment
- 480 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Kaiser Permanente Medical Center, Vallejo, California, United States
- Illinois Cancer Specialists, Arlington Heights, Illinois, United States
- University of Illinois Hospital and Health Sciences Systems, Chicago, Illinois, United States
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
- Texas Oncology, Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- University of Virginia, Charlottesville, Virginia, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Shenandoah Oncology, P.C., Winchester, Virginia, United States
- Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
- GenesisCare North Shore Health Hub, St Leonards, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07185997 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT06956690A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsHummingbird Bioscience